Natalizumab improves ambulation in relapsing−remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM

por Voloshyna, N, Havrdová, E, Hutchinson, M, Nehrych, T, You, X, Belachew, S, Hotermans, C, Paes, D
Publicado 2015

Time course of clinical and neuroradiological effects of delayed-release dimethyl fumarate in multiple sclerosis

por Kappos, L, Giovannoni, G, Gold, R, Phillips, J T, Arnold, D L, Hotermans, C, Zhang, A, Viglietta, V, Fox, R J
Publicado 2015